IP Library Granted Patent US 9,155,785
Granted Patent B2
US 9,155,785 · App. 14/283,794 · Granted Oct 13, 2015

Crystallized oxalate decarboxylase and methods of use

Inventors: Bhami C. Shenoy (South Grafton, MA); Teresa G. Cachero (Hingham, MA); John Shin (Burlington, MA); Lekai Zhang (Watertown, MA); Aftab Rashid (Natick, MA); Danica Grujic (Boston, MA); Reena J. Patel (Woburn, MA); Margaret Ellen McGrath (Somerville, MA)
Assignee: AJINOMOTO ALTHEA, INC.
A61K38/51A61K9/0034A61M1/16A61M1/3687C12N9/88C12Q1/527A61K38/00A61M2202/0413A61M2205/75C07K2299/00C12Y401/01002G01N2333/988
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,785
App. No.
14/283,794
Granted
Oct 13, 2015
Kind
B2
Abstract

Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.

Claims (18)

1. A method of reducing oxalate concentration n a mammal in need, the method comprising contacting a body fluid of the mammal with a composition comprising oxalate decarboxylase crystals in an extracorporeal device, wherein the amount of the oxalate decarboxylase crystals contained in the extracorporeal device is sufficient to reduce the concentration of oxalate in the body fluid of the mammal.

2. The method of claim 1 , wherein the oxalate decarboxylase crystals are covalently linked by a cross-linking agent.

3. The method of claim 1 , wherein said crystals are active and stable at about pH 2 to about pH 8.

4. The method of claim 1 , wherein the method results in a reduction of oxalate of at least 10% to 50%.

5. A method of treating a disorder associated with elevated oxalate concentration in a mammal, the method comprising contacting a body fluid of the mammal with oxalate decarboxylase crystals in an extracorporeal device, wherein the amount of the oxalate decarboxylase crystals contained in the extracorporeal device is sufficient to lower elevated oxalate concentration in the body fluid of the mammal, thereby reducing one or more symptoms associated with the disorder.

6. The method of claim 5 , wherein the disorder is related to a kidney or a liver function.

7. The method of claim 5 , wherein the disorder is selected from the group consisting of primary hyperoxaluria, enteric hyperoxaluria, idiopathic hyperoxaluria, and ethylene glycol poisoning.

8. The method of claim 1 , wherein the oxalate decarboxylase crystals are uncrosslinked.

9. The method of claim 1 , wherein the extracorporeal device comprises a catheter coated with the oxalate decarboxylase crystals.

10. The method of claim 1 , wherein the extracorporeal device filters waste products from the bloodstream of the mammal.

11. The method of claim 10 , wherein the extracorporeal device comprises a dialysis device or a membrane of a dialysis device.

12. The method of claim 5 , wherein the oxalate decarboxylase crystals are covalently linked by a cross-linking agent.

13. The method of claim 5 , wherein the oxalate decarboxylase crystals are uncrosslinked.

14. The method of claim 5 , wherein the extracorporeal device comprises a catheter coated with the oxalate decarboxylase crystals.

15. The method of claim 5 , wherein the extracorporeal device filters waste products from the bloodstream of the mammal.

16. The method of claim 15 , wherein the extracorporeal device comprises a dialysis device or a membrane of a dialysis device.

17. The method of claim 5 , wherein the method results in a reduction of oxalate of at least 10% to 50%.

18. The method of claim 5 , wherein said crystals are active and stable at about pH 2 to about pH 8.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: ALLENA PHARMACEUTICALS
To: GLYSCEND, INC.
Reel/Frame 065554/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2016
From: SHENOY, BHAMI C.; CACHERO, TERESA G.; SHIN, JOHN; ZHANG, LEKAI; RASHID, AFTAB; GRUJIC, DANICA; PATEL, REENA J.; MCGRATH, MARGARET ELLEN
To: ALTUS PHARMACEUTICALS, INC.
Reel/Frame 037666/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2016
From: LYNNE F. RILEY, AS CHAPTER 7 TRUSTEE OF ALTUS PHARMACEUTICALS, INC.
To: ALTHEA TECHNOLOGIES, INC.
Reel/Frame 037666/0809 →
CHANGE OF NAME Recorded Feb 4, 2016
From: ALTHEA TECHNOLOGIES, INC.
To: AJINOMOTO ALTHEA, INC.
Reel/Frame 037697/0078 →
Continuity (5)
Continuation 13372274 · Feb 13, 2012
Division 11833082 · Aug 2, 2007
Provisional Application 60854540 · Oct 26, 2006
Provisional Application 60834933 · Aug 2, 2006
Related Publication 20150004204A1 · Jan 1, 2015